Skip to main content
Equibles
GOSS logo

GOSS · Gossamer Bio, Inc.

Track GOSS — free

Use GOSS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about GOSS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.15 0.00 (-2.60%)
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has concluded that these circumstances and the uncertainties associated with the Company's ability to obtain additional equity or debt financing on terms that are favorable to the Company, or at all, and otherwise succeed in its future operations raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$73.08M
Shares
488.85M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.16 Open$0.16 Day$0.15–0.16 52W close$0.14–3.79 Avg vol 30d35.0M Short int95.0M · 19.4% float · 1.5d Short vol60% Last earningsAug 13, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 13

Up next

Next earnings call
Nov 2, 2027 Est · unconfirmed · in 63 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Strong Sell
      SellHoldBuy
      Technical Strong Sell Momentum Weak Sentiment Bearish Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 16 · calm Equity put/call 0.58
      Technical
      price trend
      Strong Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −87%
      below
      Price vs 50-day avg −6%
      below
      RSI (14) 45
      neutral
      MACD trend Negative
      52-week position 1%
      near low
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +10%
      trailing
      6-month return −63%
      trailing
      YTD return −95%
      this year
      Relative strength −74%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bearish
      Trend (MA cross) No cross
      50d $0 › 200d $1 — 200d above 50d
      Institutional flow Distributing
      -10% holders QoQ · +27 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      19.43% of float · ▲ +29.8% MoM · 1.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      173 holders — mid 3-yr range
      Squeeze score 66
      elevated · 0–100
      Fundamentals
      Weak
      Revenue growth −58%
      Y/Y
      EPS growth −200%
      Y/Y
      Free cash flow $-171.3M
      Balance sheet $37.7M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 141%
      annualized · 1-yr
      Max drawdown −96%
      past year
      ATR 11.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Strong Sell
      4 · 3 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −87% Bearish
      Price vs 50-day avg
      −6% Bearish
      RSI (14)
      45 Neutral
      MACD trend
      Negative Bearish
      52-week position
      1% Bearish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $0 › 200d $1 — 200d above 50d
      Institutional flow Distributing
      -10% holders QoQ · +27 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      19.43% of float · ▲ +29.8% MoM · 1.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      173 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $0 Now $0 · 1% Range high $4
      vs 200-day avg -87% vs 50-day avg -6%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      GOSS
      Gossamer Bio, Inc.
      this stock
      		$73.08M -94.9% -57.7% — 19.4%
      ONC
      BeOne Medicines Ltd.
      		 $557.05B +21.5% +22179.2% 856.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $136.93B +19.2% +46.2% 31.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $86.39B +7.1% +20.8% 20.8 3.3%
      MRNA
      Moderna, Inc.
      		 $69.62B +352.1% +4.3% — 12.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      173
      % held
      76.1%
      Net QoQ
      +201.8M sh
      Top holder
      D. E. Shaw & Co., Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      106
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      95.0M
      Days to cover
      1.5d
      Change
      +21.8M sh
      View
      Short Volume
      Short vol %
      60%
      As of
      Aug 20, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      251.8K
      Value
      $45.3K
      As of
      Jul 31, 2026
      View
      Off-Exchange
      Off-exchange %
      61.3%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $48.5M
      Net income (FY)
      $-170.4M
      EPS diluted
      $-0.75
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 21, 2026
      This year
      18
      View
      Exempt Offerings
      Offering
      $212.1M
      Filed
      Aug 7, 2023
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 13, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      GOSS -7.4% +10.1% -62.9% -7.4% -94.9%
      SPY -2.0% +3.3% +11.2% +2.1% +11.8%
      vs SPY -5.4% +6.8% -74.1% -9.4% -106.8%
      Key facts CIK 1728117 CUSIP 38341P102 13F (30d) 165 filings 162 filers Visit website

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)